Shenzhen Efung Investment Management (Efung Capital) is a Shenzhen based life science venture capital firm. They focus investments in clinical-stage pharmaceutical and medical device companies already generating revenues. They look for investment in China and the United States.
Efung Capital has made investments in WeMed, Elicio Therapeutics, TriArm Therapeutics, Zhongyianke Biotech, Tactiva Therapeutics, KBP Biosciences, Centrexion Therapeutics, Ascentage Pharma, Chipscreen Biosciences, Frontier Biotech, Lifotronic, Healthgen Biotech, Aridis Pharmaceuticals, and Resverlogix.
Timeline
People
Frank Luo
Managing Director
Hao Li
Medical Strategy Officer
Hao Ye
Managing Director
Hualiang Jiang
Strategy Consultant
Hui Zhao
Principal
Jie Zhang
Partner
Jinhua Lu
Partner
Jinqiao Zhu
Chairman and President
Li Hua
Principal
Ning Lei
Managing Director
Pai Zhu
Assistant President
Ran Wang
Vice President
Ruina Wang
Managing Director
Sylvia Li
Analyst
Xiaoxiao Peng, PhD
Managing Director
Yu Lei
Managing Director
Yu Wang
Chief Scientist
Yuan Gao
Principal
Zhengli Ren
Partner
Shenzhen
